Abstract: The purpose of the present invention is to develop a method for screening drugs having the effect of increasing skin barrier function in in vitro studies and to evaluate barrier function in the skin. Candidate drugs can be screened by using the activity and/or expression level of serine racemase as an indicator.

Abstract: The purpose of the present invention is to develop a method for screening drugs having the effect of increasing skin barrier function in in vitro studies and to evaluate barrier function in the skin. Candidate drugs can be screened by using the activity and/or expression level of serine racemase as an indicator.

Abstract: The present invention addresses the problem of providing a novel method for the pretreatment of a biological sample containing lenalidomide enantiomer and thereby establishing a simple and accurate method for the quantitative analysis of lenalidomide enantiomer. In the present invention, the racemization and decomposition of lenalidomide enantiomer in a biological sample can be prevented by the deproteinization under acidic conditions of the biological sample containing lenalidomide enantiomer, and the lenalidomide enantiomer can be simply and accurately quantitatively analyzed by subjecting to HPLC the biological sample that has been pretreated in such a way.

Abstract: The purpose of the present invention is to develop a method for screening drugs having the effect of increasing skin barrier function in in vitro studies and to evaluate barrier function in the skin. Candidate drugs can be screened by using the activity and/or expression level of serine racemase as an indicator.

Abstract: The purpose of the present invention is to develop a method for screening drugs having the effect of increasing skin barrier function in in vitro studies and to evaluate barrier function in the skin. Candidate drugs can be screened by using the activity and/or expression level of serine racemase as an indicator.

Abstract: The problem addressed by the present invention is to provide a novel method for separating and purifying pure enantiomer of lenalidomide. Pure enantiomer of lenalidomide can be separated and purified by using, as the mobile phase, an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols, and mixtures thereof.

Abstract: The problem addressed by the present invention is to provide a novel method for separating and purifying pure enantiomer of lenalidomide. Pure enantiomer of lenalidomide can be separated and purified by using, as the mobile phase, an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols, and mixtures thereof.

Abstract: The present invention addresses the problem of providing a novel method for the pretreatment of a biological sample containing lenalidomide enantiomer and thereby establishing a simple and accurate method for the quantitative analysis of lenalidomide enantiomer. In the present invention, the racemization and decomposition of lenalidomide enantiomer in a biological sample can be prevented by the deproteinization under acidic conditions of the biological sample containing lenalidomide enantiomer, and the lenalidomide enantiomer can be simply and accurately quantitatively analyzed by subjecting to HPLC the biological sample that has been pretreated in such a way.

Abstract: The purpose of the present invention is to develop a method for screening drugs having the effect of increasing skin barrier function in in vitro studies and to evaluate barrier function in the skin. Candidate drugs can be screened by using the activity and/or expression level of serine racemase as an indicator.

Abstract: The object of the invention is to develop a screening method for drugs having effects of increasing skin barrier function in in vitro experimentation, and to evaluate skin barrier function for skin. Serine racemase activity and/or expression level are used as an indicator to allow screening of candidate drugs.

Abstract: Disclosed is a stable and safe antioxidant composition which can be used routinely. Specifically disclosed is an antioxidant composition which contains one or more compounds selected from the group consisting of D-aspartic acid, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin conditions. The skin conditions may include, but is not limited to, fine wrinkles, a rough skin, a dry skin, a skin cancer, a skin allergy, an inflammation of the skin and a photosensitive dermatosis. The composition may be used for an external preparation for the skin, a food, and a pharmaceutical product for cataract.

Abstract: Disclosed are: a composition for alleviating ultraviolet irradiation-induced damage, which can be used on a daily based and is stable and safe; and a pharmaceutical preparation, a cosmetic and a food composition, each of which comprises the composition. The composition for alleviating ultraviolet irradiation-induced damage contains one or more compounds selected from the group consisting of D-glutamic acid, L-glutamic acid, D-proline, D-cystine, L-cystine, and derivatives and/or salts of the aforementioned compounds. The composition can be used as an external formulation for the skin, a cosmetic composition, an anti-wrinkle agent, a sunscreen agent, a pharmaceutical composition for treating and/or preventing skin diseases, a food composition, or a pharmaceutical composition for preventing or treating cataract.

Abstract: Disclosed is a novel composition which has an effect on promoting production of collagen. The composition has high photostability and is free from side effects such as those of retinoids. Specifically disclosed is a composition for promoting collagen production which contains one or more compounds selected from the group consisting of D-aspartic acid, D-alanine, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin a condition. The skin condition may include but is not limited to photoaging and/or wrinkles. The composition may be used for an external preparation for the skin or food. The composition may be a composition for promoting type I collagen production.

Abstract: Disclosed is a novel composition which has a function of stimulating production of laminin-332. The composition is stable and safe, and can be used routinely. Specifically disclosed is a laminin-332 production stimulating composition which contains one or more compounds selected from the group consisting of D-alanine, D-hydroxyproline, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving a skin condition. The skin condition may include, but is not limited to a photoaging, wrinkles, a rough skin, fine wrinkles and a dry skin. The composition may be used for an external preparation for the skin or a food.

Abstract: Disclosed are: an oral composition for alleviating ultraviolet irradiation-induced damage, which can be used on a daily basis and is stable and safe; and a medicinal agent; and anti-wrinkle agent and a food composition, each of which comprises the oral composition. Specifically disclosed is an oral composition for alleviating ultraviolet irradiation-induced damage, which comprises at least one compound selected from the group consisting of methionine and derivatives and/or salts thereof. The composition may be an anti-wrinkle agent, a pharmaceutical composition for treating and/or preventing skin diseases, a food composition, or a pharmaceutical composition for preventing or treating cataract. In the oral composition for alleviating ultraviolet irradiation-induced damage, methionine may be in the D-form.

Abstract: Provided is a novel composition that acts to inhibit and/or ameliorate wrinkle formation, does not have adverse effects like those of retinoids, and is highly photostable. An oral composition for reducing wrinkle formation and an oral composition for preventing wrinkle formation are provided, the compositions containing at least one compound selected from the group consisting of D-glutamic acid and derivatives and/or salts thereof. Also provided are a pharmaceutical composition and a food composition containing the oral composition for reducing wrinkle formation or the oral composition for preventing wrinkle formation.

Abstract: Disclosed is a novel composition which has a function of stimulating production of laminin-332. The composition is stable and safe, and can be used routinely. Specifically disclosed is a laminin-332 production stimulating composition which contains one or more compounds selected from the group consisting of D-alanine, D-hydroxyproline, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving a skin condition. The skin condition may include, but is not limited to a photoaging, wrinkles, a rough skin, fine wrinkles and a dry skin. The composition may be used for an external preparation for the skin or a food.

Abstract: Disclosed is a stable and safe antioxidant composition which can be used routinely. Specifically disclosed is an antioxidant composition which contains one or more compounds selected from the group consisting of D-aspartic acid, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin conditions. The skin conditions may include, but is not limited to, fine wrinkles, a rough skin, a dry skin, a skin cancer, a skin allergy, an inflammation of the skin and a photosensitive dermatosis. The composition may be used for an external preparation for the skin, a food, and a pharmaceutical product for cataract.

Abstract: Disclosed is a novel composition which has an effect on promoting production of collagen. The composition has high photostability and is free from side effects such as those of retinoids. Specifically disclosed is a composition for promoting collagen production which contains one or more compounds selected from the group consisting of D-aspartic acid, D-alanine, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin a condition. The skin condition may include but is not limited to photoaging and/or wrinkles. The composition may be used for an external preparation for the skin or food. The composition may be a composition for promoting type I collagen production.

Abstract: Provided is a stable and safe oral composition that acts on the barrier function of the skin for alleviating and/or preventing rough skin. An oral composition for alleviating rough skin and an oral composition for preventing rough skin are provided, the compositions containing at least one compound selected from the group consisting of D-glutamic acid and derivatives and/or salts thereof. Also provided are a pharmaceutical composition and/or a food composition containing the oral composition for alleviating rough skin or the oral composition for preventing rough skin.